ArticleJAAD international2024
Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm
Article in JAAD international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Clinical Clearance of Actinic Keratoses with Tirbanibulin 1% Ointment: Evidence from a Meta-Analysis.Life (Basel, Switzerland) · 2026Article
- Efficacy and Safety of Tirbanibulin 1% Ointment for Actinic Keratosis at 1-Year Follow-Up: A Real-Life Extension Study.Medicina (Kaunas, Lithuania) · 2026Article
- Chemoprevention in Skin Cancer: What Advice?Cancers · 2026Review
- Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- The State of the Art in the Treatment of Actinic Keratosis and Field Cancerization: A Narrative Review.Journal of personalized medicine · 2025Review
- Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights.Dermatology practical & conceptual · 2025Review
- Field Cancerization Treatment with Tirbanibulin 1% Ointment: Results in Real-World Practice.Acta dermato-venereologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tirbanibulin is approved for actinic keratosis (AK) field treatment up to 25 cm Objective: Evaluate the safety and tolerability of tirbanibulin when applied to a field of approximately 100 cm Methods: Phase 3, multicenter, open-label, single-arm study among adult patients having a treatment field on the face or balding scalp of approximately 100 cm Results: A total of 105 patients were included. The most common LTS were erythema (96.1%) and flaking/scaling (84.4%), being mostly mild-to-moderate severity, and resolved/returned to or close to baseline by Day 29. The only severe LTS were erythema (5.8%) and flaking/scaling (8.7%). Most frequent treatment emergent adverse events were application site pruritus (10.5%) and application site pain (8.6%). Mean total number of AKs decreased from 7.7 AKs at baseline to 1.8 AKs at Day 57. Mean percent of change (reduction) from baseline in lesion count was 77.8% at Day 57. Limitations: No control group. No long-term follow-up. Conclusion: Safety and tolerability profiles in patients treated with tirbanibulin up to 100 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.